336 related articles for article (PubMed ID: 27821498)
1. Established T Cell-Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade.
Moore E; Clavijo PE; Davis R; Cash H; Van Waes C; Kim Y; Allen C
Cancer Immunol Res; 2016 Dec; 4(12):1061-1071. PubMed ID: 27821498
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity.
Ager CR; Reilley MJ; Nicholas C; Bartkowiak T; Jaiswal AR; Curran MA
Cancer Immunol Res; 2017 Aug; 5(8):676-684. PubMed ID: 28674082
[TBL] [Abstract][Full Text] [Related]
3. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
[TBL] [Abstract][Full Text] [Related]
4. Induction of tumor regression by intratumoral STING agonists combined with anti-programmed death-L1 blocking antibody in a preclinical squamous cell carcinoma model.
Gadkaree SK; Fu J; Sen R; Korrer MJ; Allen C; Kim YJ
Head Neck; 2017 Jun; 39(6):1086-1094. PubMed ID: 28323387
[TBL] [Abstract][Full Text] [Related]
5. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity.
Demaria O; De Gassart A; Coso S; Gestermann N; Di Domizio J; Flatz L; Gaide O; Michielin O; Hwu P; Petrova TV; Martinon F; Modlin RL; Speiser DE; Gilliet M
Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15408-13. PubMed ID: 26607445
[TBL] [Abstract][Full Text] [Related]
6. A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice.
Foote JB; Kok M; Leatherman JM; Armstrong TD; Marcinkowski BC; Ojalvo LS; Kanne DB; Jaffee EM; Dubensky TW; Emens LA
Cancer Immunol Res; 2017 Jun; 5(6):468-479. PubMed ID: 28483787
[TBL] [Abstract][Full Text] [Related]
7. Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer.
Sato-Kaneko F; Yao S; Ahmadi A; Zhang SS; Hosoya T; Kaneda MM; Varner JA; Pu M; Messer KS; Guiducci C; Coffman RL; Kitaura K; Matsutani T; Suzuki R; Carson DA; Hayashi T; Cohen EE
JCI Insight; 2017 Sep; 2(18):. PubMed ID: 28931759
[TBL] [Abstract][Full Text] [Related]
8. Blockade of the Phagocytic Receptor MerTK on Tumor-Associated Macrophages Enhances P2X7R-Dependent STING Activation by Tumor-Derived cGAMP.
Zhou Y; Fei M; Zhang G; Liang WC; Lin W; Wu Y; Piskol R; Ridgway J; McNamara E; Huang H; Zhang J; Oh J; Patel JM; Jakubiak D; Lau J; Blackwood B; Bravo DD; Shi Y; Wang J; Hu HM; Lee WP; Jesudason R; Sangaraju D; Modrusan Z; Anderson KR; Warming S; Roose-Girma M; Yan M
Immunity; 2020 Feb; 52(2):357-373.e9. PubMed ID: 32049051
[TBL] [Abstract][Full Text] [Related]
9. ATM inhibition augments type I interferon response and antitumor T-cell immunity when combined with radiation therapy in murine tumor models.
Jin WJ; Zangl LM; Hyun M; Massoud E; Schroeder K; Alexandridis RA; Morris ZS
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730275
[TBL] [Abstract][Full Text] [Related]
10. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade.
Yang H; Lee WS; Kong SJ; Kim CG; Kim JH; Chang SK; Kim S; Kim G; Chon HJ; Kim C
J Clin Invest; 2019 Jul; 129(10):4350-4364. PubMed ID: 31343989
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Explant Responses to STING Ligands: Personalized Immunosurgical Therapy for Head and Neck Squamous Cell Carcinoma.
Baird JR; Bell RB; Troesch V; Friedman D; Bambina S; Kramer G; Blair TC; Medler T; Wu Y; Sun Z; de Gruijl TD; van de Ven R; Leidner RS; Crittenden MR; Gough MJ
Cancer Res; 2018 Nov; 78(21):6308-6319. PubMed ID: 30224374
[TBL] [Abstract][Full Text] [Related]
12. Host Immunity Following Near-Infrared Photoimmunotherapy Is Enhanced with PD-1 Checkpoint Blockade to Eradicate Established Antigenic Tumors.
Nagaya T; Friedman J; Maruoka Y; Ogata F; Okuyama S; Clavijo PE; Choyke PL; Allen C; Kobayashi H
Cancer Immunol Res; 2019 Mar; 7(3):401-413. PubMed ID: 30683733
[TBL] [Abstract][Full Text] [Related]
13. Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors.
Yi M; Niu M; Wu Y; Ge H; Jiao D; Zhu S; Zhang J; Yan Y; Zhou P; Chu Q; Wu K
J Hematol Oncol; 2022 Oct; 15(1):142. PubMed ID: 36209176
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral delivery of the chitin-derived C100 adjuvant promotes robust STING, IFNAR, and CD8
Turley JL; Ward RW; Huete-Carrasco J; Muñoz-Wolf N; Roche K; Jin L; Bowie A; Andersson M; Lavelle EC
Cell Rep Med; 2024 May; 5(5):101560. PubMed ID: 38729159
[TBL] [Abstract][Full Text] [Related]
15. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade.
Fu J; Kanne DB; Leong M; Glickman LH; McWhirter SM; Lemmens E; Mechette K; Leong JJ; Lauer P; Liu W; Sivick KE; Zeng Q; Soares KC; Zheng L; Portnoy DA; Woodward JJ; Pardoll DM; Dubensky TW; Kim Y
Sci Transl Med; 2015 Apr; 7(283):283ra52. PubMed ID: 25877890
[TBL] [Abstract][Full Text] [Related]
16. Enhancing immunotherapy of STING agonist for lymphoma in preclinical models.
Sallets A; Robinson S; Kardosh A; Levy R
Blood Adv; 2018 Sep; 2(17):2230-2241. PubMed ID: 30194137
[TBL] [Abstract][Full Text] [Related]
17. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
Fang DD; Tang Q; Kong Y; Wang Q; Gu J; Fang X; Zou P; Rong T; Wang J; Yang D; Zhai Y
J Immunother Cancer; 2019 Nov; 7(1):327. PubMed ID: 31779710
[TBL] [Abstract][Full Text] [Related]
18. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
19. Magnitude of Therapeutic STING Activation Determines CD8
Sivick KE; Desbien AL; Glickman LH; Reiner GL; Corrales L; Surh NH; Hudson TE; Vu UT; Francica BJ; Banda T; Katibah GE; Kanne DB; Leong JJ; Metchette K; Bruml JR; Ndubaku CO; McKenna JM; Feng Y; Zheng L; Bender SL; Cho CY; Leong ML; van Elsas A; Dubensky TW; McWhirter SM
Cell Rep; 2018 Dec; 25(11):3074-3085.e5. PubMed ID: 30540940
[TBL] [Abstract][Full Text] [Related]
20. Identification of Novel Carbocyclic Pyrimidine Cyclic Dinucleotide STING Agonists for Antitumor Immunotherapy Using Systemic Intravenous Route.
Vyskocil S; Cardin D; Ciavarri J; Conlon J; Cullis C; England D; Gershman R; Gigstad K; Gipson K; Gould A; Greenspan P; Griffin R; Gulavita N; Harrison S; Hu Z; Hu Y; Hata A; Huang J; Huang SC; Janowick D; Jones M; Kolev V; Langston SP; Lee HM; Li G; Lok D; Ma L; Mai D; Malley J; Matsuda A; Mizutani H; Mizutani M; Molchanova N; Nunes E; Pusalkar S; Renou C; Rowland S; Sato Y; Shaw M; Shen L; Shi Z; Skene R; Soucy F; Stroud S; Xu H; Xu T; Abu-Yousif AO; Zhang J
J Med Chem; 2021 May; 64(10):6902-6923. PubMed ID: 34000802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
